Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|April 1, 2001
- Pharmaceutical Executive-04-01-2001
- Volume 0
- Issue 0
Regulation: OK After All
Author(s)Kevin Gopal
London-The National Institute of Clinical Excellence (NICE) has decided that Roche's Xenical (orlistat) should be available from the National Health Service for managing obesity and its related problems, but it should not be viewed as a slimming pill.
Advertisement
Articles in this issue
over 25 years ago
Internet DTC - Minding Your P's & Q'sover 25 years ago
Regulation: Two-Track Planover 25 years ago
Policy: Tectonic Shiftover 25 years ago
Liberated?over 25 years ago
A Matter of Tasteover 25 years ago
Partnerships: Bargaining Biotechsover 25 years ago
Pediatric Mandateover 25 years ago
Genentech's Passion for PatientsAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
4
Closing the Pediatric Evidence Gap
5